Scar - Pipeline Review, H2 2019
Scar - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Scar - Pipeline Review, H2 2019, provides an overview of the Scar (Dermatology) pipeline landscape.
A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red to purple fibrous tissue that over time usually becomes flatter and lighter in color.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Scar - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Scar (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Scar (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Scar and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 5, 8 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.
Scar (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Scar - Pipeline Review, H2 2019, provides an overview of the Scar (Dermatology) pipeline landscape.
A scar is a permanent patch of skin that grows over a wound. Scars occur at the site of tissue damage and appear as firm red to purple fibrous tissue that over time usually becomes flatter and lighter in color.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Scar - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Scar (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Scar (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Scar and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 5, 8 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.
Scar (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Scar (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Scar (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Scar (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Scar (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Scar (Dermatology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Scar (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Scar (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Scar - Overview
Scar - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Scar - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Scar - Companies Involved in Therapeutics Development
Axolo Pharma Inc
BirchBioMed Inc
Cotinga Pharmaceuticals Inc
CSA Biotechnologies LLC
Ember Therapeutics Inc (Inactive)
FBM Therapeutics LLC
Kringle Pharma Inc
Moerae Matrix Inc
Pharmaxis Ltd
Phio Pharmaceuticals Corp
Promore Pharma AB
Resolys Bio Inc
ScarTec Therapeutics BV
Synedgen Inc
Temple Therapeutics BV
Scar - Drug Profiles
albuterol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTL-slo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Evitar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FBM-5712 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICX-RHY - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMI-0100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Fibrotic Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide for Scar and Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharide for Wounds and Scars - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXL-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Lysyl Oxidase for Scar and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SOX-9 for Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Scar - Dormant Projects
Scar - Discontinued Products
Scar - Product Development Milestones
Featured News & Press Releases
Feb 28, 2019: First patient enrolled in BirchBioMed's study investigating FS2 for the treatment of scars
Feb 01, 2019: Promore Pharma modifies its Phase III trial of PXL01 and expands the number of clinics in the study
Oct 23, 2018: Promore Pharma has had a successful meeting with the FDA regarding PXL01
Sep 03, 2018: Promore Pharma plans to expand indications of therapeutic peptide PXL01 in the field of dermal scarring
May 08, 2018: RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO
Feb 16, 2018: BirchBioMed is cleared to begin first-of-its-kind phase II clinical trial for ground-breaking anti-scarring drug
Feb 15, 2018: Promore Pharma Regains Rights for PXL01 Manufacturing
Feb 01, 2018: Promore Pharma is granted a patent for PXL01 in the US
Jan 02, 2018: Promore Pharma Adjusts Plans for PXL01 in North America
Dec 18, 2017: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring
May 17, 2017: Promore Pharma files phase III clinical trial application in India
Mar 28, 2017: RXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109
Aug 25, 2016: BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug
Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model
Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Scar - Overview
Scar - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Scar - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Scar - Companies Involved in Therapeutics Development
Axolo Pharma Inc
BirchBioMed Inc
Cotinga Pharmaceuticals Inc
CSA Biotechnologies LLC
Ember Therapeutics Inc (Inactive)
FBM Therapeutics LLC
Kringle Pharma Inc
Moerae Matrix Inc
Pharmaxis Ltd
Phio Pharmaceuticals Corp
Promore Pharma AB
Resolys Bio Inc
ScarTec Therapeutics BV
Synedgen Inc
Temple Therapeutics BV
Scar - Drug Profiles
albuterol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTL-slo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Evitar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FBM-5712 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICX-RHY - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-100IT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMI-0100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Fibrotic Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide for Scar and Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharide for Wounds and Scars - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXL-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Lysyl Oxidase for Scar and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SOX-9 for Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Scar - Dormant Projects
Scar - Discontinued Products
Scar - Product Development Milestones
Featured News & Press Releases
Feb 28, 2019: First patient enrolled in BirchBioMed's study investigating FS2 for the treatment of scars
Feb 01, 2019: Promore Pharma modifies its Phase III trial of PXL01 and expands the number of clinics in the study
Oct 23, 2018: Promore Pharma has had a successful meeting with the FDA regarding PXL01
Sep 03, 2018: Promore Pharma plans to expand indications of therapeutic peptide PXL01 in the field of dermal scarring
May 08, 2018: RXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO
Feb 16, 2018: BirchBioMed is cleared to begin first-of-its-kind phase II clinical trial for ground-breaking anti-scarring drug
Feb 15, 2018: Promore Pharma Regains Rights for PXL01 Manufacturing
Feb 01, 2018: Promore Pharma is granted a patent for PXL01 in the US
Jan 02, 2018: Promore Pharma Adjusts Plans for PXL01 in North America
Dec 18, 2017: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring
May 17, 2017: Promore Pharma files phase III clinical trial application in India
Mar 28, 2017: RXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109
Aug 25, 2016: BirchBioMed announces completion of clinical trial for ground-breaking anti-scarring drug
Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model
Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Table 1: Number of Products under Development for Scar, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 6: Products under Development by Universities/Institutes, H2 2019
Table 7: Number of Products by Stage and Target, H2 2019
Table 8: Number of Products by Stage and Mechanism of Action, H2 2019
Table 9: Number of Products by Stage and Route of Administration, H2 2019
Table 10: Number of Products by Stage and Molecule Type, H2 2019
Table 11: Scar - Pipeline by Axolo Pharma Inc, H2 2019
Table 12: Scar - Pipeline by BirchBioMed Inc, H2 2019
Table 13: Scar - Pipeline by Cotinga Pharmaceuticals Inc, H2 2019
Table 14: Scar - Pipeline by CSA Biotechnologies LLC, H2 2019
Table 15: Scar - Pipeline by Ember Therapeutics Inc (Inactive), H2 2019
Table 16: Scar - Pipeline by FBM Therapeutics LLC, H2 2019
Table 17: Scar - Pipeline by Kringle Pharma Inc, H2 2019
Table 18: Scar - Pipeline by Moerae Matrix Inc, H2 2019
Table 19: Scar - Pipeline by Pharmaxis Ltd, H2 2019
Table 20: Scar - Pipeline by Phio Pharmaceuticals Corp, H2 2019
Table 21: Scar - Pipeline by Promore Pharma AB, H2 2019
Table 22: Scar - Pipeline by Resolys Bio Inc, H2 2019
Table 23: Scar - Pipeline by ScarTec Therapeutics BV, H2 2019
Table 24: Scar - Pipeline by Synedgen Inc, H2 2019
Table 25: Scar - Pipeline by Temple Therapeutics BV, H2 2019
Table 26: Scar - Dormant Projects, H2 2019
Table 27: Scar - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 28: Scar - Discontinued Products, H2 2019
Table 1: Number of Products under Development for Scar, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Universities/Institutes, H2 2019
Table 4: Products under Development by Companies, H2 2019
Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 6: Products under Development by Universities/Institutes, H2 2019
Table 7: Number of Products by Stage and Target, H2 2019
Table 8: Number of Products by Stage and Mechanism of Action, H2 2019
Table 9: Number of Products by Stage and Route of Administration, H2 2019
Table 10: Number of Products by Stage and Molecule Type, H2 2019
Table 11: Scar - Pipeline by Axolo Pharma Inc, H2 2019
Table 12: Scar - Pipeline by BirchBioMed Inc, H2 2019
Table 13: Scar - Pipeline by Cotinga Pharmaceuticals Inc, H2 2019
Table 14: Scar - Pipeline by CSA Biotechnologies LLC, H2 2019
Table 15: Scar - Pipeline by Ember Therapeutics Inc (Inactive), H2 2019
Table 16: Scar - Pipeline by FBM Therapeutics LLC, H2 2019
Table 17: Scar - Pipeline by Kringle Pharma Inc, H2 2019
Table 18: Scar - Pipeline by Moerae Matrix Inc, H2 2019
Table 19: Scar - Pipeline by Pharmaxis Ltd, H2 2019
Table 20: Scar - Pipeline by Phio Pharmaceuticals Corp, H2 2019
Table 21: Scar - Pipeline by Promore Pharma AB, H2 2019
Table 22: Scar - Pipeline by Resolys Bio Inc, H2 2019
Table 23: Scar - Pipeline by ScarTec Therapeutics BV, H2 2019
Table 24: Scar - Pipeline by Synedgen Inc, H2 2019
Table 25: Scar - Pipeline by Temple Therapeutics BV, H2 2019
Table 26: Scar - Dormant Projects, H2 2019
Table 27: Scar - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 28: Scar - Discontinued Products, H2 2019
LIST OF FIGURES
Figure 1: Number of Products under Development for Scar, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Targets, H2 2019
Figure 5: Number of Products by Stage and Targets, H2 2019
Figure 6: Number of Products by Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
Axolo Pharma Inc
BirchBioMed Inc
Cotinga Pharmaceuticals Inc
CSA Biotechnologies LLC
Ember Therapeutics Inc (Inactive)
FBM Therapeutics LLC
Kringle Pharma Inc
Moerae Matrix Inc
Pharmaxis Ltd
Phio Pharmaceuticals Corp
Promore Pharma AB
Resolys Bio Inc
ScarTec Therapeutics BV
Synedgen Inc
Temple Therapeutics BV
Figure 1: Number of Products under Development for Scar, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Targets, H2 2019
Figure 5: Number of Products by Stage and Targets, H2 2019
Figure 6: Number of Products by Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
Axolo Pharma Inc
BirchBioMed Inc
Cotinga Pharmaceuticals Inc
CSA Biotechnologies LLC
Ember Therapeutics Inc (Inactive)
FBM Therapeutics LLC
Kringle Pharma Inc
Moerae Matrix Inc
Pharmaxis Ltd
Phio Pharmaceuticals Corp
Promore Pharma AB
Resolys Bio Inc
ScarTec Therapeutics BV
Synedgen Inc
Temple Therapeutics BV
